Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration

Background: Claims included in package inserts (PIs) for medicinal products approved by the US Food and Drug Administration (FDA) constitute the regulatory definition of drugs’ benefits and risks. Objective: We sought to assess the usage of patient-reported outcome (PRO) claims in a comprehensive se...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarosławski, Szymon, Auquier, Pascal, Borissov, Borislav, Dussart, Claude, Toumi, Mondher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956285/
https://www.ncbi.nlm.nih.gov/pubmed/29785254
http://dx.doi.org/10.1080/20016689.2018.1433426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956285/
https://www.ncbi.nlm.nih.gov/pubmed/29785254
http://dx.doi.org/10.1080/20016689.2018.1433426

Ejemplares similares